tipifarnib has been researched along with Breast Cancer in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (85.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arun, B; Buzdar, AU; Hortobagyi, GN; Moulder, SL; Murray, JL; Murthy, RK; Shroff, GS; Stalzer, CJ; Szklaruk, J; Valero, V; Yam, C; Yang, W | 1 |
| Christos, PJ; Hershman, DL; Hoschander, S; Li, T; O'Brien, K; Sparano, JA; Vahdat, LT; Wright, JJ | 1 |
| Coppola, D; Fineberg, S; Hershman, D; Hopkins, U; Hoschander, S; Kazi, A; Kleer, C; Lee, D; Li, T; Malafa, M; Merajver, S; Moulder, S; Munster, P; Negassa, A; Pellegrino, C; Sebti, SM; Sparano, JA; Vahdat, L; Wright, JJ | 1 |
| Allal, BC; Chaoui, K; Dalenc, F; Doisneau-Sixou, SF; Favre, G; Filleron, T; Lauwers-Cances, V; Malissein, E; Marsili, S; Meunier, E; Monsarrat, B; Renée, N; Roché, H; Schiltz, O | 1 |
| Gradishar, WJ; Guo, M; Li, T; Perez, EA; Sledge, GW; Sparano, JA; Wang, M | 1 |
| Adjei, AA; Dy, GK | 1 |
| Kelland, LR | 1 |
| Li, T; Sparano, JA | 1 |
| Dowsett, M; Ellis, P; Hickish, T; Houston, S; Howes, A; Johnston, SR; Kelland, L; Michiels, B; Palmer, P; Perez-Ruixo, JJ; Salter, J | 1 |
| de Bono, JS; Rowinsky, EK; Tolcher, AW | 1 |
| Balis, FM; Chow, C; Clark, G; Eng-Wong, J; Gantz, SB; Jayaprakash, N; Lebowitz, PF; Venzon, D; Widemann, BC; Zujewski, J | 1 |
| Dalenc, F; Favre, G; Faye, JC; Giamarchi, C; Petit, M; Poirot, M | 1 |
| Anderson, E; Bundred, NJ; Clarke, RB; Knox, F; Morris, J; Wärnberg, F; White, D | 1 |
| Jiang, D; Zhang, M | 1 |
| Hershman, D; Hopkins, U; Hoschander, S; Kazi, A; Lee, D; Li, T; Malafa, M; Moulder, S; Munster, P; Pellegrino, C; Sebti, SM; Sparano, JA; Vahdat, L; Wright, JJ | 1 |
| Chen, W; Chow, A; Hayes, S; Perez-Ruixo, JJ; Zhang, S | 1 |
| Awada, A; De Porre, P; de Valeriola, D; Gil, T; Lalami, Y; Piccart-Gebhart, MJ; Zhang, S | 1 |
| Bessems, A; De Porre, PM; Dodwell, DJ; Howes, AJ; Johnston, SR; Manikhas, GM; Neven, P; Park, YC; Perez Ruixo, JJ; Romieu, G; Semiglazov, VF; Spaeth, D; Wardley, AM | 1 |
| Detre, S; Dowsett, M; Head, JE; Howes, A; Johnston, SR; Kaye, S; Martin, LA; Pancholi, S; Quinn, E; Salter, J | 1 |
| Clarke, PA; Detre, S; Dowsett, M; End, D; Howes, AJ; Johnston, SR; Kelland, LR; Patterson, L; Smith, V; Valenti, M; Workman, P | 1 |
5 review(s) available for tipifarnib and Breast Cancer
| Article | Year |
|---|---|
Farnesyltransferase inhibitors in breast cancer therapy.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fluorouracil; Humans; Mice; Neoplasm Proteins; Paclitaxel; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Farnesyl transferase inhibitors in the treatment of breast cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2003 |
Inhibiting Ras signaling in the therapy of breast cancer.
Topics: Alkyl and Aryl Transferases; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Female; GTP-Binding Proteins; Humans; Mutation; Neoplasm Metastasis; Quinolones; ras Proteins; Signal Transduction | 2003 |
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Piperidines; Protein Prenylation; Proto-Oncogene Mas; Pyridines; Quinolones; ras Proteins; Signal Transduction | 2003 |
[Farnesyl transferase inhibitors--a novel agent for breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Piperidines; Protein Prenylation; Pyridines; Quinolones; ras Proteins | 2006 |
12 trial(s) available for tipifarnib and Breast Cancer
| Article | Year |
|---|---|
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quinolones; Treatment Outcome | 2018 |
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Farnesyltranstransferase; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Quinolones; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2009 |
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Farnesyltranstransferase; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Quinolones; rho GTP-Binding Proteins; STAT3 Transcription Factor | 2009 |
Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Farnesyltranstransferase; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Protein Array Analysis; Quinolones; Tamoxifen | 2010 |
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Quinolones; Taxoids; Treatment Outcome | 2012 |
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinolones; Thrombocytopenia; Treatment Outcome | 2003 |
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Exanthema; Farnesyltranstransferase; Fatigue; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Quinolones; Tamoxifen; Treatment Outcome | 2005 |
[Farnesyl transferase inhibitors--a novel agent for breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Piperidines; Protein Prenylation; Pyridines; Quinolones; ras Proteins | 2006 |
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Quinolones; Treatment Outcome | 2006 |
Exposure-toxicity relationships for tipifarnib in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Male; Middle Aged; Quinolones; Treatment Outcome | 2007 |
A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Female; Humans; Immune System; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Taxoids; Treatment Outcome | 2007 |
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Estrogen Receptor Modulators; Farnesyltranstransferase; Female; Humans; Letrozole; Middle Aged; Nitriles; Quinolones; Time Factors; Treatment Outcome; Triazoles | 2008 |
4 other study(ies) available for tipifarnib and Breast Cancer
| Article | Year |
|---|---|
Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Female; Humans; Pyrrolidines; Quinolones; Receptors, Estrogen; Tamoxifen | 2005 |
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.
Topics: Animals; Breast Neoplasms; Calcinosis; Carcinoma, Intraductal, Noninfiltrating; Cell Division; Cell Line, Tumor; Farnesyltranstransferase; Female; Humans; Mammography; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Quinolones; Transplantation, Heterologous | 2006 |
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Drug Therapy, Combination; Farnesyltranstransferase; Female; Flow Cytometry; Fluorescent Antibody Technique; G1 Phase; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; Quinolones; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transplantation, Heterologous | 2007 |
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; HT29 Cells; Humans; Immunohistochemistry; Ki-67 Antigen; Lamin Type A; Mice; Mice, Nude; Neoplasm Transplantation; Nuclear Proteins; Protein Precursors; Quinolones; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |